Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85,366 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Visit Adherence of Mild to Moderate Psoriasis Patients: A Mobile-Based Randomized Study.
Zhao Y, Wang G, Ni W, Song Z, Chen K, Zhang C, Zhang S, Ding Y, Zheng M, Shi Y, Lin Z, Liu X, Zhang X, Zhou Q, Ahmed KD. Zhao Y, et al. Among authors: zhang c, zhang s, zhang x. Patient Prefer Adherence. 2021 Jan 5;14:2551-2557. doi: 10.2147/PPA.S277103. eCollection 2020. Patient Prefer Adherence. 2021. PMID: 33447016 Free PMC article.
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C, Yang X, Yang B, Yan G, Dong X, Ding Y, Fan W, Li L, Yang D, Fang H, Ji C, Cheng H, Zhang S, Goh AH, Liu R, Gu X, Weng Z, Foley P, Sinclair R, Zhang J. Zhou C, et al. Among authors: zhang s, zhang j. J Am Acad Dermatol. 2023 Nov;89(5):911-919. doi: 10.1016/j.jaad.2023.02.063. Epub 2023 Apr 3. J Am Acad Dermatol. 2023. PMID: 37019385 Clinical Trial.
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, Xu H, Xiao R, Ding Y, Huang K, Zhang C, Zhang L, Chen B, Duan X, Pan W, Han G, Chen R, Liu L, Zhang S, Tao J, Pang X, Yu J, Wang H, Zhao Y, Li C, Kang X, Qin L, Zhu X, Su J, Li S, Yang C, Feng W, Lei T, Jiang S, Fang R, Lin M, Lu Q, Xu C, Wang W, Zhang J. Cai L, et al. Among authors: zhang l, zhang c, zhang s, zhang g, zhang j. Br J Dermatol. 2024 Aug 14;191(3):336-343. doi: 10.1093/bjd/ljae062. Br J Dermatol. 2024. PMID: 38366639 Clinical Trial.
Efficacy and Safety of a Fixed-Dose Combination Gel with Adapalene 0.1% and Clindamycin 1% for the Treatment of Acne Vulgaris (CACTUS): A Randomized, Controlled, Assessor-Blind, Phase III Clinical Trial.
Luan C, Yang WL, Yin JW, Deng LH, Chen B, Liu HW, Zhang SM, Han J, Liu ZJ, Dai XR, Yin QJ, Yu XH, Chen K, Gu H, Li BXY. Luan C, et al. Dermatol Ther (Heidelb). 2024 Nov;14(11):3097-3112. doi: 10.1007/s13555-024-01286-x. Epub 2024 Nov 1. Dermatol Ther (Heidelb). 2024. PMID: 39487326 Free PMC article.
Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial.
Zhang D, Lei T, Qin L, Li C, Lin X, Wang H, Zhang G, Zhang S, Shi K, Li L, Yang Z, Yang X, Ba X, Gao Y, Zhang Z, Wang G, Wu L, Wang Y, Wang Y, Zhu S, Shi J, Ye Z, Yang C, Liu C, Zhang T, Lu S, Yu N, Li X, Han X, Chen X, Wan L, Cheng Z, Bai N, Jin Z, Yu C, Zhang W, Lu J, Wang D, Sun H, Wu W, Qin P, Feng Z, Chen R, Zhang T, Yang D, Yin W, Zhang J, Li X, Li F, Wu T, Lu Q. Zhang D, et al. Among authors: zhang s, zhang g, zhang w, zhang t, zhang z, zhang j. JAMA Dermatol. 2024 Nov 1;160(11):1182-1191. doi: 10.1001/jamadermatol.2024.3410. JAMA Dermatol. 2024. PMID: 39320907 Free PMC article. Clinical Trial.
85,366 results
You have reached the last available page of results. Please see the User Guide for more information.